Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 2015
|
| In: |
The lancet. Haematology
Year: 2015, Volume: 2, Issue: 12, Pages: e516-e527 |
| ISSN: | 2352-3026 |
| DOI: | 10.1016/S2352-3026(15)00197-0 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/S2352-3026(15)00197-0
|
| Author Notes: | Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej J. Jakubowiak, Marc S. Raab, Thierry Facon, Prof Ravi Vij, Darrell White, Donna E. Reece, Lotfi Benboubker, Jeffrey Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil K. Singhal, Sagar Lonial, on behalf of the 1703 study investigators |
| Item Description: | Gesehen am 28.07.2016 |
|---|---|
| Physical Description: | Online Resource |
| ISSN: | 2352-3026 |
| DOI: | 10.1016/S2352-3026(15)00197-0 |